DUBLIN--(BUSINESS WIRE)--The "Central Nervous System Drugs Market Global Briefing 2018" report has been added to ResearchAndMarkets.com's offering.
The global central nervous system drugs market is expected to reach around $82 billion in 2020
Central Nervous System Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global central nervous system drugs sector.
Going forward, the growth of this market can be attributed to steps taken by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) to offer allotment of special regulatory designations for Central Nervous System disorders which will help in the faster entry of drugs into the market for treatment of serious nervous system related conditions.
The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord's ability to function is affected, hence affecting the body.
North America was the largest region in the central nervous system drugs market in 2017, accounting for around 37% market share. This can be attributed to high per capita spending on drugs to treat central nervous system disorders, the aging population and the insurance system which supports high healthcare costs in the USA. Western Europe was the second largest region accounting for around 20% market share. Asia Pacific was the third largest region accounting for around 19% market share.
Wearables to Improve R&D - Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson's disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%.
For instance, in 2016, Michael J. Fox Foundation for Parkinson's Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson's disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer's disease research.
Markets Covered: Anaesthetics, Analgesics, Anti-Parkinson drugs, Anti-Epileptics, Other CNS drugs.
Time Series: Five years historic and forecast.
Data: Market value in $ billions.
Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Biogen Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- Shire Plc.
- UCB S.A.
- Eli Lilly
- Sanofi S.A.
- Daiichi Sankyo Company Limited
For more information about this report visit https://www.researchandmarkets.com/research/44zhcn/global_central?w=4